

# Global Dilated Cardiomyopathy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

<https://marketpublishers.com/r/GF1CF584DBCEN.html>

Date: August 2019

Pages: 48

Price: US\$ 1,799.00 (Single User License)

ID: GF1CF584DBCEN

## Abstracts

High levels of pipeline activity are being observed in Dilated Cardiomyopathy treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Array BioPharma , Berlin Cures GmbH, Capricor Therapeutics Inc, Celixir Ltd, Hemostemix Inc and others.

A Significant contribution to the Dilated Cardiomyopathy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Dilated Cardiomyopathy pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Dilated Cardiomyopathy condition and increased access to investments is encouraging growth of Dilated Cardiomyopathy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Dilated Cardiomyopathy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Dilated Cardiomyopathy therapeutic candidates. Further, drugs in clinical stage including phase

1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Dilated Cardiomyopathy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Dilated Cardiomyopathy. Further, orphan drug status, fast track designation, grants awarded and other special status for Dilated Cardiomyopathy pipeline compounds are also included.

This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Dilated Cardiomyopathy pipeline and formulate effective research and development strategies.

## **RESEARCH METHODOLOGY**

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

### Scope of the Research

#### Dilated Cardiomyopathy Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Dilated Cardiomyopathy drugs

Late phase: Phase 3 and in-approval Dilated Cardiomyopathy drugs

#### Companies involved in the Pipeline-

Company overview

Snapshot

## Dilated Cardiomyopathy therapeutic treatment activities

Details for each Dilated Cardiomyopathy drug candidate-

### Snapshot

Drug Name

Alternative Names

Company

Originator

Phase

Molecule Type

Orphan Drug Status

Drug Overview

Mechanism of Action

Current Status

Trial Details

Other details

Pre-clinical trials for each drug candidate

Clinical trials for each drug candidate

Recent Dilated Cardiomyopathy therapeutic candidates, clinical trials, investments,

*Global Dilated Cardiomyopathy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therap...*

grants, partnerships, licenses, awards and other news

## Contents

### 1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

### 2 EXECUTIVE SUMMARY

- 2.1 Dilated Cardiomyopathy- Disease Overview
- 2.2 Dilated Cardiomyopathy- Pipeline Snapshot
- 2.3 Dilated Cardiomyopathy- Pipeline Drugs by Phase
- 2.4 Dilated Cardiomyopathy- Pipeline Drugs by Company
- 2.5 Dilated Cardiomyopathy- Pipeline Drugs by Mechanism of Action

### 3 COMPANY WISE PIPELINE ANALYSIS

- 3.1 Array BioPharma Dilated Cardiomyopathy Drug Pipeline, H2- 2019
- 3.2 Berlin Cures GmbH Dilated Cardiomyopathy Drug Pipeline, H2- 2019
- 3.3 Capricor Therapeutics Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
- 3.4 Celixir Ltd Dilated Cardiomyopathy Drug Pipeline, H2- 2019
- 3.5 Hemostemix Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
- 3.6 Martin Pharmaceuticals Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
- 3.7 MyoKardia In Dilated Cardiomyopathy Drug Pipeline, H2- 2019
- 3.8 Renovacor Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019

### 4 PHASE 1 PIPELINE DRUG DETAILS

- 4.1 Dilated Cardiomyopathy- Phase 1 Drug Details
- 4.2 Dilated Cardiomyopathy- Phase 1 Drug Overview
- 4.3 Dilated Cardiomyopathy- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

### 5 PHASE 2 PIPELINE DRUG DETAILS

- 5.1 Dilated Cardiomyopathy- Phase 2 Drug Details
- 5.2 Dilated Cardiomyopathy- Phase 2 Drug Overview
- 5.3 Dilated Cardiomyopathy- Phase 2 Mechanism of Action

5.4 Current Status

5.5 Trial Details

## **6 PHASE 3 PIPELINE DRUG DETAILS**

6.1 Dilated Cardiomyopathy- Phase 3 Drug Details

6.2 Dilated Cardiomyopathy- Phase 3 Drug Overview

6.3 Dilated Cardiomyopathy- Phase 3 Drug Mechanism of Action

6.4 Current Status

6.5 Trial Details

## **7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS**

7.1 Dilated Cardiomyopathy- Pre-clinical Phase Drug Details

7.2 Dilated Cardiomyopathy- Pre-clinical Phase Drug Overview

7.3 Dilated Cardiomyopathy- Pre-clinical Phase Drug Mechanism of Action

7.4 Current Status

7.5 Trial Details

## **8 RECENT NEWS AND DEVELOPMENTS**

## **9 APPENDIX**

9.1 About VPAResearch

9.2 Sources and Research Methodology

## I would like to order

Product name: Global Dilated Cardiomyopathy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Product link: <https://marketpublishers.com/r/GF1CF584DBCEN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF1CF584DBCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

